How Much Muscle Do You Lose on GLP-1 Medications?

Bottom line Some lean mass is usually lost during substantial weight reduction, whether weight loss occurs through medication, diet, or surgery. In the SURMOUNT-1 body-composition substudy, about 75% of the weight lost with tirzepatide (Zepbound) was fat mass and about 25% was lean mass. Lean mass is not identical to skeletal muscle, and preserving strength requires attention to protein, resistance exercise, total nutrition, and the pace of weight loss. The same principles apply to any medicine that produces substantial weight loss, including the Wegovy pill and Foundayo.

The headline can be misleading

Articles sometimes state that a quarter of the weight lost on a GLP-1 medication is “muscle.” That wording is too imprecise. Body-composition studies generally measure lean mass or fat-free mass. These categories include skeletal muscle but also water, organs, connective tissue, and other nonfat tissue. A reduction in measured lean mass does not automatically equal proportional loss of functional muscle.

What did the tirzepatide body-composition study show?

A DXA substudy of SURMOUNT-1 assessed body composition in 160 adults with obesity or overweight (124 on tirzepatide and 36 on placebo), a small subset of the 2,539 people in the trial. By week 72, body weight had fallen 21.3% with tirzepatide versus 5.3% with placebo. Fat mass fell 33.9% and lean mass fell 10.9% with tirzepatide (8.2% and 2.6% with placebo). Of the weight lost, approximately 75% was fat mass and 25% was lean mass, a proportion broadly consistent with many effective weight-loss interventions. Visceral fat and waist circumference also declined. (Look et al., 2025)

Other studies report a wider range. A 2024 review (Neeland et al.) found that lean mass made up about 15% or less of the weight lost in some trials and 40% to 60% in others, and that MRI-based studies suggest muscle changes are about what would be expected for a person’s age, health and the amount of weight lost. Differences in who was studied and how lean mass was measured explain much of the variation.

The clinical objective is not to eliminate every reduction in lean mass; that is unrealistic during major weight loss. The objective is to maximize fat loss while preserving strength, mobility, metabolic health, and as much skeletal muscle as reasonably possible.

Who deserves extra attention?

• Adults over 65, especially those with frailty, falls, or low baseline muscle mass.
• Patients who sharply reduce food intake because nausea or appetite suppression is excessive.
• People consuming little protein or relying mainly on snack foods and refined carbohydrates.
• Patients with prolonged inactivity, neurologic disease, or recent hospitalization.
• People losing weight very rapidly without resistance training.
• Patients with kidney disease or other conditions that require individualized protein targets.

Four practical ways to protect muscle and function

1. Make protein intake deliberate

Appetite suppression can make inadequate protein surprisingly easy. A patient may eat far less but also replace balanced meals with toast, crackers, soup, or small salads. A common practical approach is to distribute protein across meals rather than attempt to consume most of it at dinner.

For a number to aim at, the federal Dietary Guidelines for Americans 2025–2030 (released January 2026) give a general goal of 1.2 to 1.6 grams of protein per kilogram of body weight per day. For a person who weighs 80 kg (176 lb), that is roughly 96 to 128 grams a day. A 2024 review of muscle preservation on these medicines (Mechanick et al.) cites 1.2 to 1.5 grams per kilogram for adults over 65 and notes that protein beyond these levels has an unclear benefit for preserving muscle. A July 2026 perspective from the American Society for Nutrition concludes that the evidence for a higher range for everyone falls short. Treat these numbers as a starting point to discuss with us. Protein needs should be individualized, especially in older adults and in anyone with kidney disease. Our eating guide for Zepbound and Wegovy shows how to build protein into the day.

2. Perform progressive resistance exercise

Walking supports cardiovascular health but is not a complete substitute for resistance training. Two or three weekly sessions that progressively challenge major muscle groups can help preserve strength and functional capacity. Federal physical activity guidelines call for muscle-strengthening activity on two or more days a week. The program must match baseline fitness, joint health, fall risk, and medical status. If you do not have weights at home, see our dumbbell alternatives.

3. Avoid excessive under-eating

The strongest appetite suppression is not always the best dose. Persistent nausea, vomiting, dehydration, dizziness, or inability to meet basic nutritional needs warrants clinical review. Dose escalation should be based on effectiveness and tolerability, not on reaching the highest labeled dose as quickly as possible.

4. Track function, not only weight

Useful monitoring can include waist circumference, strength progression, ability to rise from a chair, walking speed, exercise performance, dietary intake, and selected body-composition measures. Consumer scales can be directionally useful but are not precise enough to diagnose sarcopenia by themselves.

What about creatine?

Creatine is the supplement patients ask about most. In healthy adults it improves strength and lean mass when combined with resistance training, but no randomized trial has yet reported results in people taking GLP-1 medicines. We treat it as an option to discuss, not a proven add-on. Our article on creatine and GLP-1 medications covers the research, dosing, and kidney-related precautions.

Belite Clinical Perspective The relevant question is not simply “Did lean mass fall?” It is “Did the patient become healthier, stronger, and more functional while losing predominantly fat?” A well-designed obesity program combines medication with nutrition and resistance training rather than treating the prescription as the entire intervention.

Frequently asked questions

Does Wegovy or Zepbound directly destroy muscle?

Current evidence does not support that simple claim. Some lean mass declines as total weight falls, but the proportion varies and may reflect the general physiology of weight loss.

How much protein should I aim for?

The federal Dietary Guidelines for Americans 2025–2030 give a general goal of 1.2 to 1.6 grams per kilogram of body weight per day. Experts disagree about whether everyone needs that much, and people with kidney disease may need a lower target, so we set it with you. See our eating guide.

Should everyone take a protein supplement?

Not necessarily. Supplements can be useful when food intake is inadequate, but total diet, preferences, and tolerance matter.

Should I take creatine?

It is not proven for people on GLP-1 medicines, and it needs resistance training to do much. If you are interested, talk with us first so we can review your kidney labs and hydration. See creatine and GLP-1 medications.

Does this apply to the Wegovy pill and Foundayo?

The body-composition figures above come from tirzepatide. The same principles apply to any medicine that produces substantial weight loss: enough protein, resistance training, avoiding excessive under-eating, and tracking function. See the Wegovy pill and Foundayo pages for how those medicines work.

Is rapid weight loss dangerous for muscle?

Faster loss may increase concern when protein intake and resistance exercise are inadequate, particularly in older or frail patients. The appropriate rate is individualized.

Can a body-composition scale tell me whether I am losing muscle?

It can show trends, but hydration changes can substantially affect readings. Clinical interpretation should incorporate strength and function.

How BeLite Can Help

BeLite can review protein intake, dose tolerability, weight-loss pace, and practical resistance-training goals as part of ongoing medical weight management. See the medicines we prescribe on our Our Medications page, including Zepbound and Wegovy.

Last medically reviewed: November 5, 2026. This article is for general education and is not a substitute for medical advice.

Primary references

1. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27:2720-2729. Source
2. Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16-27. Source
3. Mechanick JI, Butsch WS, Christensen SM, et al. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev. 2024;e13841. Source
4. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity. Joint advisory of the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society. 2025. Source
5. Cava E, Yeat NC, Mittendorfer B. Preserving healthy muscle during weight loss. Adv Nutr. 2017;8:511-519. Source
6. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2025–2030 (released January 7, 2026). Full document (copy hosted by NMSU Extension)
7. American Society for Nutrition. Perspective in the Journal of Nutrition on protein recommendations in the 2025–2030 Dietary Guidelines (July 24, 2026). nutrition.org